The first patient implants of the Cognis (Boston Scientific) cardiac resynchronisation therapy defibrillator (CRT-D) were successfully performed in China’s Zhejiang province and Beijing by Farong Shen in Zhejiang Lucheng Hospital and Wei Hua in Beijing Fuwai Hospital.
Boston Scientific stated in a press release that the Cognis CRT-D has been launched in the Chinese market.
Cognis offers Electronic Repositioning, with six pacing configurations, to manage high pacing thresholds and unwanted diaphragmatic muscle stimulation. SmartDelay AV Optimisation provides individualised therapy without the need for an echocardiogram. Cognis also offers HF Perspectiv, a proprietary suite of diagnostics, including Heart Rate Variability Footprint which gives clinicians an objective view of patients’ response to therapy, according to a press release.
These features are paired with three left ventricular leads designed to reach and remain in the target vessel. In the press release it said that the Boston Scientific Endotak Reliance defibrillation leads have a 98.5% survival probability at 10 years, the highest in the industry.
The Cognis CRT-D is, according to the company, the thinnest in the world with exceptional longevity. Cognis battery technology is the culmination of seven years of research and is unique to Boston Scientific. The projected life expectancy of Cognis products reaches more than eight years. Longer-lasting CRT-Ds may significantly reduce the risk of a secondary operation and lessen the financial burden incurred from device replacement.
Wei Hua, chief physician of cardiovascular department in Fuwai Hospital, China, commented: “The Boston Scientific CRT-D System provides clinicians with many implantation choices, including different forms of the left ventricular lead, which I believe drives a high success rate of CRT-D implantation.”
“COGNIS is small and thin, but it has a long service life,” said Farong Shen, executive hospital director and head of the cardiology centre in Lucheng Hospital. “I believe that it is indeed a ground breaking CRT-D product for patients.”